Table 4.
Favourable clinical and microbiological response at the TOC visit by key baseline pathogen from site of skin infection and infection composition (ME population)
| Favourable clinical response, n/N (%)a |
Favourable microbiological response, n/N (%)a |
|||
|---|---|---|---|---|
| ceftaroline fosamil (n = 181) | vancomycin + aztreonam (n = 112) | ceftaroline fosamil (n = 181) | vancomycin + aztreonam (n = 112) | |
| Gram-positive pathogens | ||||
| Staphylococcus aureus | ||||
| MSSA | 88/94 (93.6) | 49/57 (86.0) | 91/94 (96.8) | 49/57 (86.0) |
| MRSA | 21/25 (84.0) | 12/15 (80.0) | 22/25 (88.0) | 12/15 (80.0) |
| Streptococcus pyogenes | 14/15 (93.3) | 7/7 (100.0) | 14/15 (93.3) | 7/7 (100.0) |
| Streptococcus agalactiae | 5/6 (83.3) | 7/9 (77.8) | 6/6 (100.0) | 9/9 (100.0) |
| Streptococcus dysgalactiae | 9/9 (100.0) | 0 | 9/9 (100.0) | 0 |
| Enterococcus faecalis | 4/6 (66.7) | 4/5 (80.0) | 5/6 (83.3) | 4/5 (80.0) |
| Gram-negative pathogens | ||||
| Escherichia coli | 11/12 (91.7) | 9/10 (90.0) | 12/12 (100.0) | 9/10 (90.0) |
| Klebsiella pneumoniae | 5/7 (71.4) | 3/4 (75.0) | 6/7 (85.7) | 3/4 (75.0) |
| Klebsiella oxytoca | 4/4 (100.0) | 1/1 (100.0) | 4/4 (100.0) | 1/1 (100.0) |
| Proteus mirabilis | 6/7 (85.7) | 2/2 (100.0) | 6/7 (85.7) | 2/2 (100.0) |
| Morganella morganii | 4/4 (100.0) | 2/2 (100.0) | 4/4 (100.0) | 2/2 (100.0) |
| Infection composition | ||||
| monomicrobial | 113/125 (90.4) | 69/80 (86.3) | 116/125 (92.8) | 69/80 (86.3) |
| polymicrobial | 50/56 (89.3) | 28/32 (87.5) | 51/56 (91.1) | 29/32 (90.6) |
aPercentages are based on total number in the treatment group with the baseline pathogen.